Elranatamab Access Study for Patients with Multiple Myeloma
Sponsor: Pfizer
ClinicalTrials ID:NCT06057402
This study provides continued access to the drug elranatamab for patients with Multiple Myeloma who have been benefiting from it in previous studies. Participants will keep receiving the treatment as long as it helps them and is not yet available in their country.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is designed to allow patients with Multiple Myeloma to continue receiving the drug elranatamab if they have been benefiting from it in earlier studies sponsored by Pfizer. The study is open-label, meaning all participants know they are receiving elranatamab, and it is single-arm, meaning there is no comparison group. Patients will continue the treatment until their disease worsens, they experience unacceptable side effects, they choose to stop, the study ends, or the drug becomes available in their country.
Description
In this study, patients with Multiple Myeloma who have been part of previous studies and are still benefiting from elranatamab will continue to receive the drug. The treatment will go on until the disease progresses, side effects become too severe, the patient decides to stop, the study ends, or the drug becomes available for purchase in their country. This ensures that patients who are responding well to elranatamab can maintain their treatment without interruption.
Eligibility Criteria
Inclusion Criteria
- Must agree to follow specific reproductive guidelines outlined in the study.
- Must have completed a previous study with elranatamab, still be receiving it when that study ended, and be benefiting from it according to the study doctor.
Exclusion Criteria
- Any medical or mental health condition, including recent or active thoughts of self-harm, that could increase the risk of participating or make the patient unsuitable for the study.
- Patients who were not part of a previous elranatamab study or who stopped treatment in a previous study cannot join this study.
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.